Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T15:01:50.091Z.
Calculation as of: 2026-10-06T15:01:50.091Z.
Quote observation: 2026-10-06T15:00:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 396f74b358d2be52688229160785b883c1ccba5e7e57b4b59ce0869c705c56f9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$403.47M
Price/FCF Ratio
N/A
TTM Avg
4285.33
3Y Avg
985.66
5Y Avg
501.76
Market Cap
$410.08M
Price/FCF Ratio
N/A
TTM Avg
6.66
3Y Avg
6.66
5Y Avg
6.66
Market Cap
$416.44M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$388.72M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$429.68M
Price/FCF Ratio
N/A
TTM Avg
53.84
3Y Avg
53.84
5Y Avg
53.84
Market Cap
$383.60M
Price/FCF Ratio
N/A
TTM Avg
1258.06
3Y Avg
1258.06
5Y Avg
226.77
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Carlsmed, Inc. (CARL) | $406.14M | N/A | N/A | N/A | N/A |
| Neurogene Inc. (NGNE)vs › | $409.28M | N/A | N/A | N/A | N/A |
| Myriad Genetics, Inc. (MYGN)vs › | $403.47M | N/A | 4285.33 | 985.66 | 501.76 |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $410.08M | N/A | 6.66 | 6.66 | 6.66 |
| Shoulder Innovations, Inc. (SI)vs › | $411.45M | N/A | N/A | N/A | N/A |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $416.44M | N/A | N/A | N/A | N/A |
| MapLight Therapeutics, Inc. (MPLT)vs › | $388.72M | N/A | N/A | N/A | N/A |
| Editas Medicine, Inc. (EDIT)vs › | $429.68M | N/A | 53.84 | 53.84 | 53.84 |
| Orthofix Medical Inc. (OFIX)vs › | $383.60M | N/A | 1258.06 | 1258.06 | 226.77 |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $383.01M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
